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Background: Serum levels of the soluble LR11 fragment (sLR11) increase in patients with acute 
leukemia.  
Results: Hypoxia-induced HIF-1α activation increases LR11 levels, and sLR11 enhances adhesion of 
HSPCs to BM stromal cells via a uPAR-mediated pathway. 
Conclusion: sLR11 regulates hypoxia-induced attachment of HSPCs.  
Significance: sLR11 may stabilize the hematological pool size by controlling HSPC attachment to the 
BM niche. 
 
 
 SUMMARY 
A key property of hematopoietic stem and progenitor cells (HSPCs) regarding differentiation 
from the self-renewing quiescent to the proliferating stage is their adhesion to the bone marrow 
(BM) niche. An important molecule involved in proliferation and pool size of HSPCs in the BM 
is the hypoxia-induced uPAR. Here we show that the soluble form (sLR11) of LR11 (also called 
SorLA or SORL1) modulates the uPAR-mediated attachment of HSPCs under hypoxic 
conditions. Immunohistochemical and mRNA expression analyses revealed that hypoxia 
increased LR11 expression in hematological c-Kit(+) Lin(-) cells. In U937 cells, hypoxia induced 
a transient rise in LR11 transcription, production of cellular protein, and release of sLR11. 
Attachment to stromal cells of c-Kit(+) Lin(-) cells of lr11-/- mice was reduced by hypoxia much 
more than of lr11+/+ animals. sLR11 induced the adhesion of U937 and c-Kit(+) Lin(-) cells to 
stromal cells. Cell attachment was increased by sLR11 and reduced in the presence of 
anti-uPAR antibodies. Furthermore, the fraction of uPAR co-immunoprecipitated with LR11 in 
membrane extracts of U937 cells was increased by hypoxia. CoCl2, a chemical inducer of 
HIF-1α, enhanced the levels of LR11 and sLR11 in U937 cells. The decrease in hypoxia-induced 
attachment of HIF-1α knockdown cells was largely prevented by exogenously added sLR11. 
Finally, hypoxia induced HIF-1α binding to a consensus binding site in the LR11 promoter. 
Thus, we conclude that sLR11 regulates the hypoxia-enhanced adhesion of HSPCs via an 
uPAR-mediated pathway that stabilizes the hematological pool size by controlling cell 
attachment to the BM niche.  
 
 Hypoxic conditions play a key role in the regulation of the pool size of hematopoietic stem and 
progenitor cells (HSPCs) in the bone marrow (BM) through the regulation of many molecules 
expressed in HSPCs (1,2) . The partial pressure of oxygen (pO2) of the endosteal sites is known to be 
much lower than that of the nearest capillaries (3). Long-term hematopoietic stem cells (LT-HSCs) 
reside mainly in the endosteum (4-6), and are stained with pimonidazole, a chemical probe for 
hypoxia (7-9). Accordingly, human cord blood HSCs transplanted into immuno-deficient mice require 
a hypoxic status to maintain cell cycle quiescence in the BM (10).  
One of the key regulatory functions of the molecules in the HSPCs under hypoxia is the modulation of 
cell adhesion to the osteoblastic niche in order to facilitate the differentiation from the immature 
quiescent self-renewal stage to the down-stream proliferating mature hematological cell stage (1,2,11). 
Many proteins including Sca-1, cKit, CD34, and urokinase-type plasminogen activator receptor 
(uPAR; CD87) have been identified as regulators of HSPCs adhesion to osteoblastic niches (12-17). 
In fact, recent studies using overexpressing or knockout mice and cells for Angiopoietin-1 (Ang-1), 
Thrombopoietin (TPO), BMP-4, Secreted frizzled related protein-1 (Sfrp-1), or uPAR have shown 
that changes in expression of the respective gene cause disturbed maintenance of normal HSPC pool 
size and lead to pathological conditions typical of hematological proliferative disease or severe 
anemia (2). In fact, uPAR has been shown to be a major regulator of proliferation, marrow pool size, 
engraftment, and mobilization of murine HSPCs (17). Together with previous results of analyses of 
uPAR as a prognosis marker in leukemic patients (18), disturbed regulation of uPAR may be 
important in the pathogenesis of leukemias involving uPAR-expressing malignant cells. Although 
uPAR expression is known to be induced by hypoxia in cultured hematological cells (19), the 
mechanism underlying the upregulation of uPAR under hypoxic conditions has not yet been 
elucidated. 
We have identified and characterized a regulator of uPAR function, LR11 (also called SorLA or 
SORL1), in vascular smooth muscle cells (SMCs) (20,21). LR11 is a type I membrane protein, from 
which a large soluble extracellular part, sLR11, is released by proteolytic shedding (20,22-24). sLR11 
accelerates intimal thickening and macrophage-foam cell formation in the process of atherosclerosis 
(25). Recent studies in humans and animals have shown that sLR11 is produced by myeloid cells after 
 
 G-CSF treatment, and that the released sLR11 plays an important role in the G-CSF-induced 
leukocyte mobilization from BM to the circulation (Shimizu et al., unpublished observation). Zhang et 
al. reported high levels of LR11 mRNA in human CD34(+) CD38(-) immature hematopoietic 
precursors (26). Both LR11 mRNA and cell surface protein levels are elevated in immature leukemic 
cells, in turn leading to increased levels of sLR11 in acute leukemias (27). Thus, it is conceivable that 
in hypoxic environments, modulation of uPAR expression by sLR11 may be important for 
maintenance of the HSPC pool size.  
Here, we have studied the regulation of LR11 expression in hematological cells under hypoxic 
conditions such as those found in the BM niche. Immature and mature hematological cells in the BM 
express LR11 in hypoxia-sensitive fashion. HIF-1α activation by hypoxia or chemical means leads to 
increased LR11 expression, which in turn enhances the adhesion of leukemia cells to stromal cells 
through direct interaction of sLR11 with uPAR. Regulation of uPAR by LR11 may provide the basis 
for a novel strategy towards maintenance of the hematological cell pool size via modification of uPAR 
functions in hypoxic niches of the BM. 
 
 EXPERIMENTAL PROCEDURES 
Mice—All animal studies were reviewed and approved by the Special Committee on Animal 
Welfare, School of Medicine, at the Inohana Campus of Chiba University. Lr11-/- mice (21) 
were maintained under standard animal house conditions with a 12 h light/dark cycle, and were fed ad 
libitum with regular chow diet. 
Antibodies, Recombinant Proteins—Monoclonal antibodies (A2-2-3, M3, R14) against LR11 have 
been described previously (28). M3 was used for immunoprecipitation and ELISA, A2-2-3 for 
immunoblotting, and R14 for immunohistochemistry and ELISA. Polyclonal antibodies against uPAR 
and HIF-1α were from R&D systems and Cell Signaling Technology, respectively. Recombinant 
LR11 protein lacking the 104 C-terminal amino acids containing the transmembrane region (sLR11) 
was prepared as described (22). 
Cells—The human promonocytic cell line U937 and the human myeloid cell line K562 were 
purchased from ATCC. Human mesenchymal stem cells (MSCs) were purchased from Lonza. The 
mouse stromal cells, OP-9, were provided by Dr. Osawa (Chiba University). For murine cell sorting, 
BM cells were first stained with biotinylated-anti-Lineage (Lin) [CD5, B220, CD11b, Gr-1, 7-4, 
Ter-119] followed by incubating with streptavidin-microbeads (Miltenyi Biotec). After washing with 
staining buffer (PBS containing 0.5% BSA and 2mM EDTA), Lin(+) and Lin(-) cells, respectively, 
were enriched using magnetically activated cell sorting (MACS) columns. For mouse c-Kit(+) Lin(-) 
cell sorting, Lin(-) enriched cells were stained with anti-c-Kit microbeads (Miltenyi Biotec), then 
cKit(+) Lin(-) cells were enriched using MACS columns. U937 cells and K562 cells were cultured in 
RPMI 1640 medium supplemented with 10% FBS. MSCs were cultured in MSC growth medium, 
MSCGM (basal medium with growth supplements, Lonza), and were used between passages 2 and 5. 
OP-9 cells were cultured in DMEM, supplemented with 20% FBS. Lin(-) cells and c-Kit(+) Lin(-) 
cells were cultured in IMDM with 20% FBS. For hypoxia treatment, the cells were cultured in a 
humidified multigas incubator (APM-30D; Astec) with 1% O2 and 5% CO2 at 37 °C. 
Cell Adhesion Assay—Cell adhesion was determined in 96-well plates as described (22). For 
experiments using vitronectin-coated plates, wells were coated with 10 ng/well vitronectin for 2 h at 
37 °C. For the preparation of OP-9- and MSCs-coated plates, OP-9 and MSCs were seeded onto 
96-well plates 24 h at 37 °C, respectively, to obtain a confluent cell layer before experiments. Freshly 
purified mouse primary cells or U937 cells were fluorescently labeled by loading with Calcein 
acetoxymethylester (Calcein AM, BD Bioscience) for 1 h at 1 x 107 cells/ml in HBSS containing 1% 
BSA. Calcein-loaded cells were added to the vitronectin-, OP-9-, or MSCs-coated plates at 3 x 104 
cells/well. After centrifugation, the culture plates were incubated for 20 min at 37 °C to allow the cells 
to attach to the coated plates. Non-attached cells were removed by gently washing 3 times with PBS, 
and the attached cells were quantitated by measuring fluorescence intensity using a fluorescence 
microplate reader (SPECTRAmax GEMINI XS, Molecular Devices). The numbers of attached cells 
were determined from standard curves generated by serial dilutions of known numbers of labeled 
cells.  
LR11-overexpressing cells, LR11-knockdown cells, and HIF-1α knockdown cells—For the generation 
of LR11-overexpressing cells, transient transfection of U937 cells and transfection for stable 
expression in K562 cells were carried out with pBKCMVhLR11 (29) or pBK-CMV (mock) by using 
the Neon electroporation device (Invitrogen) according to the manufacturer’s guidelines. Stable 
transfectants were selected in medium supplemented with 800 μg/ml G418 (Roche), and maintained 
in medium containing 400 μg/ml G418. For the generation of LR11-knockdown cells, Lentiviral 
vectors (CS-H1-shRNA-EF-1α-EGFP) expressing short hairpin RNAs (shRNAs) that target two 
different sequence regions in human LR11 cDNA (#1, 5’,-GGATCATGATTCAGGAACA-3’and #5, 
5’-GGAGAGAGCATATGGAAGA-3’), and that target luciferase as control (Cosmo Bio) were 
constructed. The virus particles were produced as previously described (30). Briefly, plasmid DNA 
was transfected into 293T cells along with the packaging plasmid (pCAG-HIVgp) and the VSV-G and 
 
 Rev-expressing plasmid (pCMV-VSV-G-RSV-Rev) by calcium phosphate coprecipitation. Stable 
shRNA-expressing U937 cells were generated by infection with the supernatants from transfected 
293T cells in the presence of 5 μg/ml protamine sulfate for 24 h with subsequent sorting of the 
GFP-positive cells using FACS Aria (BD Biosciences). For the generation of HIF-1α knockdown cells, 
HIF-1α small interfering RNA (siRNA) and control siRNA were designed and synthesized by Ambion. 
These siRNAs were transfected into U937 cells by using the Neon electroporation device according to 
the manufacturer’s guidelines.  
Western Blotting, Immunoprecipitation—Sorted cells or cultured cells were washed 3 times with PBS 
and harvested in ice-cold RIPA buffer with protease inhibitors (Complete Mini, Roche). Cell lysates 
were recovered in the supernatant after centrifugation at 20,000 g for 30 min. Protein concentrations 
were determined using the BCA protein assay kit (Thermo Scientific). Samples were mixed with an 
equal volume of 2x Laemmli sample buffer containing 5% β-mercaptoethanol and heated for 5 min at 
90 °C. Where indicated, cells were incubated with sLR11 (1 μg/ml) at 37 °C for 15 min, harvested, 
and 10 ng of mouse anti-LR11 antibody (M3) or mouse IgG was added and incubated at 4°C 
overnight under mixing. The LR11/uPAR/antibody complex was bound to Protein G Sepharose. The 
proteins were released into Laemmli sample buffer containing 5% β-mercaptoethanol by heating to 
90 °C for 10 min. Protein samples were subjected to SDS-PAGE, and the immunoreactive signals 
were detected by mouse monoclonal antibody against LR11 (A2-2-3), goat polyclonal antibody 
against uPAR, or rabbit polyclonal antibody against human HIF-1α, followed by horseradish 
peroxidase (HRP)-conjugated anti-mouse, anti-goat, or anti-rabbit IgG, respectively. Development 
was performed with the ECL detection reagents (GE Healthcare). The signals were quantified with 
ChemiDoc XRS+ system using Image-Lab software (Bio-Rad).  
RNA Extraction and Real-Time Quantitative PCR Analysis—Total RNA was isolated using the 
RNeasy Kit (QIAGEN). RNA was eluted and quantified using the Nanodrop spectrometer 
(Thermo Scientific). The reverse transcription step was performed with the TaqMan Reverse 
Transcription Reagent Kit (Applied Biosystems) according to the manufacturer’s guidelines. LR11 
mRNA levels were determined by quantitative real-time PCR on the cDNA samples using the TaqMan 
assay-on-demand kit with the ABI-PRISM 7000 (Applied Biosystems). Analysis was carried out in 
triplicates in a volume of 20 μl for LR11 and the endogenous reference gene 18S rRNA, which does 
not change in hypoxia (31), and the comparative threshold cycle method was used. In each experiment, 
the RNA prepared from a sample obtained from normoxic conditions was used as calibrator to allow 
comparison of relative mRNA levels. 
Flow Cytometric Analysis—For the analysis of uPAR expression, cells were washed with PBS and 
incubated at 4 °C in the dark for 30 min with phycoerythrin (PE)-conjugated anti-uPAR antibody 
(BioLegend). Isotype control antibody (BD pharmingen) was used as a negative control. Flow 
cytometric analyses were performed with a FACSCant II (BD Biosciences). 
ELISA—Amounts of soluble LR11 released into the culture medium were determined by sandwich 
ELISA as previously reported (27). Briefly, culture media were concentrated by using Amicon 
Ultra-15 (100,000 NMWL membranes from Millipore), the concentrated sample was reacted with the 
capture monoclonal antibody M3, and then incubated with the biotinylated reporter rat monoclonal 
antibody R14. The LR11-Mab complex was reacted with HRP-conjugated streptavidin. A standard 
curve was constructed using purified LR11 protein.  
Chromatin Immunoprecipitation Assay—U937 cells were cross-linked with 1% formaldehyde for 10 
min at room temperature, followed by the addition of 0.125 M glycine and incubation for 5 min at 
4 °C. After washing with PBS, 1 x 107 cells were lysed with cell lysis buffer (50 mM Tris-HCl (pH 
8.0), 10 mM EDTA, 150 mM NaCl, 0.5% SDS, and protease inhibitors on ice, and sonicated until the 
DNA fragments had an average size 200-500 base pairs using a Bioruptor (Cosmo Bio). After 
centrifugation at 15,000 rpm for 10 min, sheared chromatin was diluted 10-fold in dilution buffer (50 
mM Tris-HCl (pH 8.0), 150 mM NaCl, 1.1% Triton X-100, 0.11% sodium deoxycholate, and protease 
 
 inhibitors. After incubation with Dynabeads Protein G (Invitrogen) for 1 h at 4°C, the precleared 
chromatin was immunoprecipitated overnight at 4°C with anti-HIF-1α antibodies (clone H1alpha67, 
Abcam)/Dynabeads Protein G mix. Beads were then sequentially washed with the following 
combination of wash buffers; twice each with low salt wash buffer (50 mM Tris-HCl (pH 8.0), 150 
mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, and 0.1% Sodium deoxycholate), high salt 
wash buffer (50 mM Tris-HCl (pH 8.0), 500 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, 
and 0.1% Sodium deoxycholate), and LiCl wash buffer (10 mM Tris-HCl (pH 8.0), 250 mM LiCl, 1 
mM EDTA, 0.5% NP40, and 0.5% Sodium deoxycholate), and TE buffer. Bound chromatin together 
with input DNA was released from the antibodies/Protein G beads by elution buffer (50 mM Tris-HCl 
(pH 8.0), 10 mM EDTA, and 1% SDS), and crosslinking was reversed by incubation in the same 
buffer overnight at 65 °C. Immunoprecipitated DNA or input DNA was treated with RNaseA (Sigma) 
and proteinase K (Roche), and then extracted with phenol:chloroform for subsequent PCR analysis. 
The primers used in this analysis spanned 144 bp around the putative HIF-1-binding site within the 
LR11 promoter (sense, 5’-GCGCTCGCTGCCTTAACTTC-3’, and antisense, 
5’-CCAGGTCCCGCTCGGTTC-3’), and 166 bp around that in the CD18 promoter as control (32). 
Statistics—The results are shown as mean ± SD for each index. 1-way ANOVA was used to compare 
between 2 groups, and Dunnett’s multiple-range test was used for comparison of multiple groups. A 
value of P < 0.05 was considered significant.  
 
 
 RESULTS 
Expression of LR11 in murine HSPCs and human U937 cells is induced by hypoxic conditions—First, 
we investigated LR11 expression levels of HSPCs under low-oxygen conditions by immunochemistry. 
Protein extracts of c-Kit(+) Lin(-) cells or Lin(+) cells, representing HSPCs, were subjected to 
immunoblot analysis with the monoclonal antibody against LR11, R14 (28) (Fig. 1). The LR11 levels 
in the c-Kit(+) Lin(-) cells were significantly lower than those of the differentiated Lin(+) cells under 
normoxic conditions. However, the LR11 expression levels in the c-Kit(+) Lin(-) cells progressively 
increased with prolonged exposure to the hypoxic conditions, whereas the levels in the Lin(+) cells 
remained relatively constant. These results indicate that the hematological cells in the BM express 
LR11, and that the expression in HSPCs is induced by hypoxic conditions. In order to analyze the 
regulation of sLR11 expression in hypoxic environments in detail, we investigated the effects of 
hypoxic conditions on LR11 expression in U937 cells, an undifferentiated leukemia cell line (33). 
When the cells were incubated under hypoxic conditions, the LR11 mRNA levels increased 15-fold 
over the levels under normoxic conditions after 3 h, and then declined within 24 h (Fig. 2A). 
Importantly, the LR11 protein in the hypoxic cells was elevated after 6 h compared to normoxic cells, 
and increased to 3-fold of the unchanged control levels after incubation for 48 h (Fig. 2B). The 
amount of sLR11 released from the cells was also increased after 48 h incubation under hypoxia (Fig. 
2C). Thus, hypoxia induced a transient increase in the transcription of the LR11 gene and subsequent 
production of cellular protein, accompanied by release of the shed form into the media.  
LR11 mediates the hypoxia-induced adhesion of immature hematological cells and HSPCs to stromal 
cells—As hypoxia has been shown to induce HSPCs adhesion (34,35), the above results suggested 
that the enhanced expression of LR11 may contribute to the hypoxia-induced adhesion of HSPCs to 
osteoblastic niches. In order to test for such a role of LR11, we analyzed the effects of LR11 
knockdown on the adhesion of U937 cells to MSCs. As shown in Fig. 3A, hypoxic conditions failed 
to stimulate adhesion of the U937 clone with largely reduced LR11 expression (see insert in Fig. 3A), 
but the enhanced adhesion was readily observed in control cells. We, therefore, analyzed the effect of 
LR11 knockout on the adhesion of HSPCs to OP-9 murine stromal cells under hypoxia. Under 
normoxic conditions, the numbers of c-Kit(+) Lin(-) cells from lr11-/- and lr11+/+ mice that attached to 
the stromal cells were not significantly different. However, while the adhesion of both lr11-/- and 
lr11+/+ cells was significantly increased under hypoxic conditions (Fig. 3B), the enhancement of 
adhesion of the lr11-/- cells was significantly less than that of lr11+/+ cells. Thus, LR11 functions in the 
hypoxia-increased adhesion to stromal cells of HSPCs and undifferentiated hematological cells. In 
order to identify the exact function of sLR11 in hypoxia-induced adhesion of HSPCs to stromal cells, 
we analyzed the effects of exogenously added sLR11 on this process. Incubation of U937 cells with 
sLR11 for 2 h drastically increased the numbers of cells attached to MSCs (Fig. 4A). Consistent with 
the effects of exogenously added sLR11 on cell adhesion, LR11-overexpressing U937 cells showed 
significantly increased adhesion in comparison to the control U937 cells (Fig. 4B). Furthermore, 
incubation with sLR11 induced the adhesion of c-Kit(+) Lin(-) cells to OP-9 cells in dose-dependent 
fashion (Fig. 4C). These results indicate that sLR11 is an important component of the pathway that 
mediates the stimulation of HSPC adhesion to stromal cells.  
Hypoxia induces the adhesion of U937 cells to stromal cells via formation of an 
LR11/uPAR-complex—sLR11 enhances adhesion of SMCs through signaling via uPAR and integrins 
(21), and hypoxia leads to increased expression of uPAR in cultured hematological and other cells 
(19,36,37). Therefore, we examined whether uPAR also is a player in the sLR11-mediated adhesion of 
hematological cells. Incubation of U937 cells with sLR11 for 2h increased in dose-dependent fashion 
the number of cells attached to vitronectin-coated plates (Fig. 5A, left). Vitronectin is an extracellular 
partner of uPAR in receptor-mediated processes underlying cell attachment (38). Indeed, the adhesion 
of c-Kit(+) Lin(-) cells to vitronectin-coated plates was increased by incubation with sLR11 in the 
same dose range (Fig. 5A, right) as that of U937 cells. The increase in numbers of attached cells upon 
 
 incubation with sLR11 was completely abolished in the presence of anti-uPAR antibodies, but was 
only non-significantly reduced in the absence of exogenously added sLR11 (Fig. 5B). 
Immunoprecipitation analysis of membrane extracts of U937 previously incubated with sLR11 
showed that uPAR was co-precipitated with sLR11, and that the amounts of both proteins increased 
after exposure of the cells to hypoxia for 24 h (Fig. 5C). Finally, flow cytometric analysis (Fig. 5D) of 
LR11-overexpressing K562 cells (see insert; LR11 was not immunologically detectable in control 
K562 cells) showed increased surface uPAR levels in comparison to mock-transfected cells. These 
data suggest that under hypoxic conditions, the increased amounts of sLR11 stimulate uPAR-mediated 
adhesion of immature hematological cells by enhancing the formation of LR11/uPAR-complexes.  
LR11 expression is dependent on HIF-1α-mediated signals—In order to gain insight into the 
mechanism underlying the induction of LR11 production by hypoxia, we tested whether changes in 
HIF-1α levels affect LR11 production. HIF-1α expression was increased by exposure of U937 cells to 
1%, but not to 5%, oxygen (Fig. 6A). The response of HIF-1α expression to oxygen deprivation was 
the same as that of LR11, suggesting a functional link between LR11 and hypoxia-induced molecules 
such as HIF-1α. We therefore analyzed the effects of cobalt chloride (CoCl2), a chemical inducer of 
HIF-1α (39), on the expression of LR11 in the cells under normoxia. CoCl2 dose-dependently 
increased the LR11 levels in U937 cells (Fig. 6B) and also the amounts of sLR11 released into the 
conditioned media (Fig. 6C). Thus, a chemical enhancer of HIF-1α induced the production of sLR11 
independent of hypoxia. Finally, using HIF-1α-knockdown cells, we directly examined the role of 
HIF-1α in the sLR11-mediated adhesion of U937 cells under hypoxic conditions. The attachment of 
HIF-1α-knockdown U937 cells to MSCs was not enhanced by exposure to hypoxia, but importantly, 
the enhancing effect was largely recovered by addition of sLR11 (Fig. 6D). These results show that 
activation of HIF-1α by hypoxia increases the expression of LR11, and in turn the production of 
sLR11. Thus, the action of HIF-1α in increasing the sLR11 levels under hypoxic conditions is 
responsible for enhancing the adhesion of hematological cells to stromal cells. 
Hypoxia induces HIF-1α binding to the potential binding site in LR11 promoter—We finally 
investigated the molecular mechanism underlying the interaction between the adhesion modulator of 
hematological cells, LR11, and the hypoxia-induced molecule, HIF-1α. HIF-1 has been shown to be a 
dominant effector of changes in transcription in response to hypoxia (39). In this context, we 
identified a potential HIF-1-binding site in the human LR11 gene promoter sequence spanning 5000 
bp before the LR11 transcription start point. This site contains the HIF-1 core sequence 5′
-ACGTG-3′ (40) between nucleotides -65 and -61 (Fig. 7A). We therefore performed chromatin 
immunoprecipitation (ChIP) analysis in order to determine whether HIF-1α binds to this region of the 
LR11 promoter in U937 cells subjected to hypoxic conditions. As shown in Fig. 7B, ChIP analysis of 
nuclei derived from U937 cells grown under hypoxia revealed an increased level of amplified 144 bp 
product corresponding to the region encompassing the potential HIF-1 binding when compared to the 
nuclei from cells in normoxia. The pattern of amplified products was similar to that for the 
HIF-1-binding site in the promoter of CD18 (32), while no significant differences were observed in 
preimmunoprecipitation input samples between normoxia and hypoxia. These results strongly suggest 
that HIF-1α binds to the proximal 144-bp LR11 promoter in a region that bears the potential 
HIF-1-binding site, and that this binding is induced by hypoxia. 
 
 
  
DISCUSSION 
In this study, we have shed light on the mechanism underlying the regulation of HSPC homeostasis 
by LR11 under the hypoxic conditions found in the BM. Hypoxia increases the level of LR11 in, and 
of sLR11 produced by, undifferentiated leukemic U937 and c-Kit(+) Lin(-) cells. LR11 levels 
correlate with the extent of adhesion of HSPCs and U937 cells to stromal cells and exogenously 
added sLR11 enhances HSPC adhesion to BM stromal cells. sLR11 originates from cellular LR11, 
and therefore the induction of LR11 under hypoxic conditions is crucial for regulating the adhesion of 
HSPCs. Interestingly, previous studies have shown that uPAR expression is induced by hypoxia in 
cultured hematological cells (19). Furthermore, using uPAR-deficient mice, Tjwa et al. reported that 
membrane-anchored uPAR regulates HSPC adhesion and BM engraftment (17), and we have shown 
that sLR11 binds to and colocalizes with uPAR on the cell surface of SMCs (41). On the basis of these 
findings, we now demonstrate that the hypoxia-induced increase in LR11 was accompanied by an 
elevated level of uPAR, which forms a complex with LR11, and leads to enhanced HIF-1α- dependent 
adhesion of HSPCs. Taken together, these data suggest that the HIF-1α-mediated induction of LR11 
expression by the hypoxic conditions in endosteal sites plays a key role in the adhesion of immature 
hematological cells to stromal cells via modulation of uPAR activity.  
We suggest that the regulatory pathway operates via an increase of LR11, enhanced release of sLR11, 
and subsequent binding of uPAR to the cell surface of HSPCs in an autocrine and/or paracrine fashion. 
In this context, we previously showed that sLR11 derived from the cell surface enhances cell adhesion 
through the activation of uPAR and integrin-mediated signals (21,41,42). On the other hand, LR11 in 
intracellular vesicles (SorLA) is important for the intracellular traffic of amyloidβ protein in neurons 
(43), and SNPs in the LR11/SORL1 gene and/or sLR11 levels in the cerebrospinal fluid have been 
reported to be a prospective marker of Alzheimer’s disease (44,45). Thus, both the released soluble 
form and the intracellular vesicle-enclosed form of LR11 may contribute to the regulation of adhesion 
properties of HSPCs under hypoxic conditions.  
The present study revealed a high sensitivity of HSPCs, but not of mature hematological cells, to 
hypoxic conditions (see Fig. 1). Together with the previous observations that sLR11 is produced only 
by immature SMCs and not in mature SMCs in atherosclerotic arteries (21), and that high levels of 
LR11 mRNA are expressed in human CD34(+) CD38(-) immature hematopoietic progenitors (26), 
sLR11 released from immature cells may strengthen cell attachment to other stromal cells or 
extracellular matrices. In this context, preliminary results suggest that sLR11 is a potent enhancer of 
TNF-α-induced attachment of hematological cells to stromal cells in response to G-CSF treatment 
(Shimizu et al., unpublished observation). 
The pO2 in BM is approximately 55 mmHg, and the oxygen saturation is 87.5% (46). Several studies 
have suggested that long term HSCs reside mainly in the endosteal sites of the BM, in which the pO2 
is very low (3,6). Cell biological studies using HS(P)Cs indicated that their functions as well as their 
quiescence state is maintained most effectively under hypoxic conditions (10,47-52). Hypoxia 
stabilizes the HIF-1α protein, a master regulator of oxygen homeostasis, and activates 
HIF-1α-mediated signals in HSCs (48,53,54). Furthermore, leukocyte adhesion to activated 
endothelial cells was shown to be HIF-1α-dependent (32). However, acute severe hypoxia induces 
HIF-1α-independent cell adhesion of monocyte/macrophage to endothelial cells (55). Therefore, 
although the hypoxia-mediated LR11 expression clearly is regulated by HIF-1α, the possible roles of 
HIF-independent cascades in LR11 regulation need to be further investigated. In any case, the current 
observation of HIF-1α-dependent regulation of LR11 expression contributes novel details to our 
understanding of the mechanism(s) underlying hypoxia-inducible adhesion of U937 cells to 
endothelial cells in the stem cell niche. 
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FIGURE LEGENDS 
 
FIGURE 1. Hypoxia induces expression of LR11 in HSPCs. After incubation for 24 h or 48 h under 
normoxic or hypoxic conditions, the LR11 expression levels in c-Kit(+) Lin(-) cells and Lin(+) cells 
were evaluated by immunoblot analysis as described in “Experimental Procedures”. The 
LR11-specific signals at 250 kDa were quantified using the Image-Lab software. The blot shown is 
representative of 3 independent experiments. Data are presented as mean ± SD (n=3). * p<0.05; ns, 
not significant. 
  
FIGURE 2. Effects of hypoxia on LR11 mRNA levels and on sLR11 production by U937 cells. A. 
LR11 mRNA expression in U937 cells after incubation under normoxic or hypoxic conditions for 3, 6, 
and 24 h were analyzed by quantitative PCR as described in “Experimental Procedures”. mRNA 
levels are represented as fold increase of those at 0 h. Data are presented as mean ± SD (n=3). * 
p<0.05; ns, not significant. B. After incubation under normoxic or hypoxic conditions for 6, 24, and 
48 h, LR11 expression levels in U937 cells were analyzed by immunoblot analysis. The LR11-specific 
signals at 250 kDa were quantified using the Image-Lab software. The blot shown is representative of 
3 independent experiments. Data are presented as mean ± SD (n=3). * p<0.05; ns, not significant. C. 
The concentrations of sLR11 in conditioned media of U937 cells incubated under normoxic or 
hypoxic condition for 48 h were determined by ELISA as described in “Experimental Procedures”. 
Data are presented as mean ± SD (n=3). * p<0.05. 
 
FIGURE 3. Effects of manipulating LR11 levels on the hypoxia-induced adhesion of immature 
hematological cells. A. After incubation in hypoxic or normoxic conditions for 24 h, the numbers of 
attached U937 cells, either transfected with shRNA specific for LR11 (#1 or #5) or with control 
shRNA (Ctrl), to MSCs were determined as described in “Experimental Procedures”. Inset: LR11 
levels in normal and LR11-knockdown U937 cells were analyzed by immunoblot. Data are shown as 
-fold increase of those at control cells without hypoxic conditions and presented as mean ± SD (n=3). 
* p<0.05; ns, not significant. B. After incubation in normoxic or hypoxic conditions for 24 h, the 
numbers of c-Kit(+) Lin(-) cells prepared from LR11+/+ or LR11-/- mice attached to OP-9 cells were 
determined as described in “Experimental Procedures”. Data are presented as mean ± SD (n=3). * 
p<0.05.  
 
 
 FIGURE 4. Effects of sLR11 on HSPC adhesion to bone marrow stromal cells. A. U937 cells 
pre-incubated for 2 h with the indicated concentrations of sLR11 were subjected to analyses of their 
adhesion to plates coated with MSCs as described in “Experimental Procedures”. B. Cells transiently 
transfected with cDNA specific for LR11 or with an empty vector (mock) were subjected to adhesion 
analyses as described for panel A. Inset: LR11 expression of mock-transfected and 
LR11-overexpressing U937 cells were analyzed by immunoblotting. C. c-Kit(+) Lin(-) cells 
pre-incubated for 15 min with the indicated concentrations of sLR11 were subjected to analyses of 
their adhesion to plates coated with OP-9 cells as described in “Experimental Procedures”. In panels A 
to C, the numbers of attached cells are presented as -fold increase of those under control conditions 
(Mean ± SD, n=3). * p<0.05; ns, not significant.   
 
FIGURE 5. Significance of LR11/uPAR-complex formation in hypoxia-induced adhesion of U937 
cells. A. U937 cells (left panel) or c-Kit(+) Lin(-) cells (right panel) pre-incubated for 2 h with the 
indicated concentrations of sLR11 were subjected to analyses of their adhesion to plates coated with 
vitronectin as described in “Experimental Procedures”. The numbers of attached cells are presented as 
-fold increase over those without sLR11 (Mean ± SD, n=3). * p<0.05; ns, not significant. B. U937 
cells pre-incubated for 4 h with or without 1 ng/ml sLR11 in the presence of anti-uPAR neutralizing 
antibody (αuPAR) or of control IgG (C. IgG) were subjected to analyses of their adhesion to plates 
coated with MSCs as described in “Experimental Procedures”. The numbers of attached cells are 
presented as -fold increase of those without sLR11 or without antibodies (Mean ± SD, n=3). * p<0.05; 
ns, not significant. C. U937 cells pre-incubated for 24 h under normoxic or hypoxic conditions were 
incubated with 10 ng/ml sLR11 for 15min, the cell lysates were immunoprecipitated with the 
monoclonal anti-LR11 antibody M3 (αLR11) or with control IgG (C. IgG) and subjected to 
immunoblot analysis with the monoclonal anti-LR11 antibody A2-2-3 or with polyclonal antibodies 
against uPAR, respectively, as described in “Experimental Procedures”. The signals for LR11 (250 
kDa) or uPAR (65 kDa) were quantified using the Image-Lab software. D. K562 cells stably 
transfected with cDNA specific for LR11 or vector alone (mock) were subjected to flow cytometric 
analysis as described in “Experimental Procedures”. The profiles of surface uPAR expression are 
presented in histograms. The frequencies and the mean fluorescence intensities (MFIs) of the fractions 
of cells with high uPAR levels are indicated. The filled histograms are isotype controls. 
Representative data from multiple experiments are shown. Inset: LR11 levels in control or 
LR11-overexpressing K562 cells were analyzed by immunoblot using the monoclonal anti-LR11 
antibody, A2-2-3. 
 
FIGURE 6. Functional link between HIF-1α and LR11 in enhancing hypoxia-induced cell adhesion. 
A. After incubation for 24 h under normoxic or hypoxic conditions (1% O2 and 5% CO2), LR11 and 
HIF-1α protein levels were evaluated by immunoblot analysis with the monoclonal anti-LR11 
antibody A2-2-3, or with polyclonal antibodies against HIF-1α, respectively, as described in 
“Experimental Procedures”. The specific signals for LR11 (250 kDa) and HIF-1α (120 kDa) were 
quantified using the Image-Lab software. B. U937 cells incubated for 48 h with the indicated 
concentrations of CoCl2 were subjected to immunoblot analysis using monoclonal anti-LR11 antibody 
A2-2-3 as described in “Experimental Procedures”. The LR11-specific signals at 250 kDa were 
quantified using the Image-Lab software. The blot shown is representative of 3 independent 
experiments. Data are presented as mean ± SD (n=3). * p<0.05; ns, not significant. C. Conditioned 
media collected after incubation for 48 h with the indicated concentrations of CoCl2 were 
concentrated and subjected to sLR11 measurement by ELISA as described in “Experimental 
Procedures”. Data are presented as mean ± SD (n=3). * p<0.05; ns, not significant. D. After 
incubation in normoxic or hypoxic conditions for 24 h with or without 1 ng/ml sLR11, the numbers of 
U937 cells previously transfected with siRNA specific for HIF-1α or with control siRNA attached to 
 
  
MSCs were counted. U937 cells incubated for 4 h in the presence or absence of 1 ng/ml sLR11 after 
pre-incubation for 24 h under normoxic or hypoxic conditions were subjected to analyses of their 
adhesion to plates coated with MSCs as described in “Experimental Procedures”. Data are shown as 
-fold increase compared to control cells in the absence of sLR11 under normoxia. Data are presented 
as mean ± SD (n=3). * p<0.05; ns, not significant. 
 
FIGURE 7. Binding of HIF-1α to the potential binding site in the CD18 promoter. A. The nucleotide 
sequence including a potential HIF-1α binding site within the LR11 gene promoter is shown. The 
motif 5′-ACGTG-3′ spanning nucleotides -65 to -61 is boxed, and the sequences corresponding to 
the forward and reverse primers are shown with arrows. B. HIF-1α binding to the LR11 and CD18 
promoter in normoxic and hypoxic conditions was examined using chromatin immunoprecipitation 
(ChIP) analysis in U937 cells. Chromatin-associated DNA (Input) prior to immunoprecipitation with 
anti- HIF-1α antibody was used for PCR controls. The amplified products were consistent with the 
expected size of fragments for LR11 (144 bp) and CD18 (166 bp) promoters, and the amplified 
sequences were confirmed to be identical to those expected, respectively. The photo shown is 
representative of 3 independent experiments. 
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